Collegium Pharmaceutical, Inc. Deferred Offering Costs
Collegium Pharmaceutical, Inc. (COLL) had Deferred Offering Costs of $112.00 thousand as of 2017-06-30, per its 10-Q filed 2017-08-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2017-08-09
- 2017-06-30: Deferred Offering Costs $112.00K.
- 2017-03-31: Deferred Offering Costs $112.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2017-06-30 | $112.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $112.00K 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |